Targeted therapies have offered striking improvements in survival rates among white patients who are diagnosed with clear cell renal cell carcinoma (ccRCC) in recent years, but survival rates for African Americans have not budged.
Renal Cell Carcinoma
The majority of renal cell carcinomas harbor VHL tumor-suppressor gene deletions that cause tumor addiction to extracellular cystine—and cystine deprivation triggers tumor cell necrosis.
A new combination therapy for treating advanced renal cell carcinoma (RCC) is showing promise in early clinical testing and may soon be approved the US Food and Drug Administration (FDA).
Investigators at Rutgers Cancer Institute of New Jersey have just published a new study in the journal Cell Reports, which suggests an entirely new way of identifying and potentially treating patients with kidney tumors.
Pembrolizumab (Keytruda), a PD-1 or “checkpoint” inhibitor, is showing promise against metastatic renal cell carcinoma (RCC), and now is being tested in a phase II trial to determine what effects it may have when combined with bevacizumab (Avastin) in patients with metastatic kidney cancer.
The targeted therapy, nivolumab (Opdivo, Bristol Myers Squibb), improved median overall survival by 5.4 months among patients with previously treated renal cell carcinoma (RCC) compared to standard of care everolimus (Afinitor).
A new genomic analysis is confirming that papillary renal cell carcinoma (PRCC) can be divided into two main subtypes.
A special formula made of titanium and gold may be able to combat renal cell carcinoma in a whole new way. In a study published in the journal Chemical Science, researchers report this combination may be more be effective than cisplatin and also associated with little toxicity.
Nivolumab (Opdivo) may help improve overall survival and with fewer grade 3 or 4 adverse events compared to everolimus (Afinitor) in previously treated advanced renal cell carcinoma, according to new results from the CheckMate 025 phase III clinical trial presented at the 2015 European Cancer Congress in Vienna, Austria, September 25-29, 2015.
Cabozantinib significantly delayed progression of disease compared with everolimus in patients with advanced clear cell renal cell carcinoma.